Biomarin Pharmaceutical Inc (BMRN)
66.00
-0.60
(-0.90%)
USD |
NASDAQ |
Nov 04, 16:00
66.00
0.00 (0.00%)
After-Hours: 20:00
Biomarin Pharmaceutical Research and Development Expense (Annual): 746.77M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 746.77M |
| December 31, 2022 | 649.61M |
| December 31, 2021 | 628.79M |
| December 31, 2020 | 628.12M |
| December 31, 2019 | 715.01M |
| December 31, 2018 | 696.33M |
| December 31, 2017 | 610.75M |
| December 31, 2016 | 661.90M |
| December 31, 2015 | 634.81M |
| December 31, 2014 | 461.54M |
| December 31, 2013 | 354.78M |
| December 31, 2012 | 302.22M |
| December 31, 2011 | 214.37M |
| Date | Value |
|---|---|
| December 31, 2010 | 147.31M |
| December 31, 2009 | 115.12M |
| December 31, 2008 | 93.29M |
| December 31, 2007 | 78.60M |
| December 31, 2006 | 66.74M |
| December 31, 2005 | 56.39M |
| December 31, 2004 | 49.78M |
| December 31, 2003 | 54.81M |
| December 31, 2002 | 27.29M |
| December 31, 2001 | 22.58M |
| December 31, 2000 | 34.46M |
| December 31, 1999 | 26.34M |
| December 31, 1998 | 10.50M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
628.12M
Minimum
2020
746.77M
Maximum
2023
673.66M
Average
649.61M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Merck & Co Inc | 30.53B |
| Bristol-Myers Squibb Co | 9.299B |
| Alnylam Pharmaceuticals Inc | 1.004B |
| Bioventus Inc | 13.45M |
| Moderna Inc | 4.845B |